Scinai Immunotherapeutics Ltd. (SCNI) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Scinai Immunotherapeutics Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Prev close 1.57 · gapped above the open, then crossed back over prior close. High/low 1.96 at 5:30 am ET, 1.35 at 4:15 pm ET.
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
No case yet. It builds on the next filing, report or 13F period.
No peer readings for Scinai Immunotherapeutics Ltd. yet.
tall tick = annual report · 1 on record
SCNI (Scinai Immunotherapeutics Ltd.) has 1 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
10 managers report a position worth $47,513 between them, and 6 of them hold 80% of it.